Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab (AK105) in Advanced Solid Tumors
NCT04172506Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab in solid tumor, lung cancer and hepatocellular carcinoma (HCC), sponsored by Akeso, Inc. Primary endpoint: Objective Response Rate up to 2 years. Started Sep 2019; status: completed.
02
Drugs
penpulimab
03
Conditions
solid tumorlung cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04172506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172506.